Toggle navigation
About Bio-Path
Leadership Team
Board of Directors
Scientific Advisory Board
Partnering Opportunities
Technology
Pipeline
Prexigebersen
BP1002
BP1003
Investors
Analyst Coverage
SEC Filings
Corporate Governance
Media
Press Releases
Events
Presentations & Publications
Careers
Contact Us
Press Releases
Press Releases
Events
Presentations & Publications
Our press releases
Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock
Feb 18 2021
Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock
Feb 16 2021
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
Feb 13 2021
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology
Feb 10 2021
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
Nov 19 2020
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS
Nov 13 2020
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
Nov 6 2020
Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers
Oct 22 2020
Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Sep 9 2020
BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
Aug 14 2020
Show More Posts
Loading...
Events
View Our Events
Presentations & Publications
View Our Publications
Delivering a Better Path for Cancer Patients.